Company intelligence / Profile preview

Latus Bio

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Preclinical gene therapies showing high CNS specificity and low off-target activity in NHP models; first-in-human dosing for CLN2 planned in late 2025; IND cleared for LTS-101 in CLN2 disease with Fast Track, Orphan Drug, and Rare Pediatric designations.

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapyAAV based gene therapy
Industry: Biotech

Partnerships

Hereditary Disease Foundation

Beyond the preview

Go deeper on Latus Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latus Bio.

Explore the full profile